

Data from Boehringer's oncology pipeline to be presented at ESMO:

Abstract Title	Presenter	ESMO Session
Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 1	Sanjay Popat	Proffered paper session: NSCLC metastatic Berlin Auditorium - Hub 27 <ul style="list-style-type: none"> October 17, 2025 4:35 – 4:45 PM CEST
Circulating tumor DNA (ctDNA) analysis following zongertinib treatment in patients with pretreated human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC): Phase 1a/1b Beamion LUNG-1 study	John Heymach	Poster session: NSCLC metastatic Hall 25 <ul style="list-style-type: none"> October 18, 2025 12:00 – 12:45 PM CEST
Beamion BCGC-1: A phase 1b/II, randomized, open-label, multicenter trial of oral zongertinib, alone or in combination, for the treatment of advanced HER2-positive metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC)	Sara A. Hurvitz	e-Poster (available via searchable screens located onsite in ePoster Area)
DAREON®-8: A phase I trial of first-line obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC)	Solange Peters	Mini oral: Non-metastatic NSCLC Hamburg Auditorium CityCube A <ul style="list-style-type: none"> October 18, 2025 4:40 – 4:45 PM CEST
DAREON®-9: A Phase Ib open-label dose escalation and dose confirmation study of obrixtamig (BI 764532) plus topotecan in patients with advanced SCLC: updated results	Martin Wermke	Poster session: SCLC Hall 25 <ul style="list-style-type: none"> October 18, 2025 12:00 – 12:45 PM CEST
Obrixtamig (BI 764532) in patients with relapsed/refractory DLL3 -high expressing epNEC: trial in progress of the dose expansion part of the Phase II DAREON®-5 trial	Marianne E. Pavel	Poster session: Neuroendocrine tumors Hall 25 <ul style="list-style-type: none"> October 20, 2025 12:00 – 12:45 PM CEST
Phase Ia results for systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Progress to date	Eileen E. Parkes	Mini oral session: Investigational immunotherapy Nuremberg Auditorium - Hall 5.2 <ul style="list-style-type: none"> October 17, 2025 14:35 – 14:40 PM CEST
An open-label, Phase Ib trial to assess the safety and efficacy of SIRPα monoclonal antibody BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with head and neck squamous cell carcinoma (NCT06806852)	Simon Laban	Poster session: Head and neck, excluding thyroid Hall 25 <ul style="list-style-type: none"> October 20, 2025 12:00 – 12:45 PM CEST
Ezabenlimab (BI 754091) and induction mDCF (modified docetaxel, cisplatin, and 5-fluorouracil) followed by adaptive chemoradiotherapy in patients (pts) with stage III squamous cell anal carcinoma (SCAC): final results of the Phase II INTERACT-ION study	Stefano Kim	Poster session: Developmental therapeutics Hall 25 <ul style="list-style-type: none"> October 19, 2025 12:00 – 12:45 PM CEST
Real-world outcomes of nintedanib plus docetaxel for adenocarcinoma NSCLC after failure of first-line immunochemotherapy: The non-interventional VARGADO study	Christian Grohe	Poster session: NSCLC metastatic Hall 25 <ul style="list-style-type: none"> October 18, 2025, 12:00 – 12:45 PM CEST